Anti-myeloma activity of pamidronate in vivo

Madhav V. Dhodapkar; Joginder Singh; Jayesh Mehta; Athanasios Fassas; K. R. Desikan; Martin Perlman; Nikhil C. Munshi; Bart Barlogie

doi:10.1046/j.1365-2141.1998.00976.x

Anti-myeloma activity of pamidronate in vivo

Madhav V. Dhodapkar, Joginder Singh, Jayesh Mehta, Athanasios Fassas, K. R. Desikan, Martin Perlman, Nikhil C. Munshi, Bart Barlogie

Research output: Contribution to journal › Article › peer-review

90 Scopus citations

Abstract

Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (≥20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.

Original language	English
Pages (from-to)	530-532
Number of pages	3
Journal	British Journal of Haematology
Volume	103
Issue number	2
DOIs	https://doi.org/10.1046/j.1365-2141.1998.00976.x
State	Published - 1998
Externally published	Yes

Keywords

Bisphosphonates
Bone
Growth
Myeloma
Pamidronate

Access to Document

10.1046/j.1365-2141.1998.00976.x

Cite this

@article{18000380dbc54c3387fd8082129a32d8,

title = "Anti-myeloma activity of pamidronate in vivo",

abstract = "Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (≥20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.",

keywords = "Bisphosphonates, Bone, Growth, Myeloma, Pamidronate",

author = "Dhodapkar, {Madhav V.} and Joginder Singh and Jayesh Mehta and Athanasios Fassas and Desikan, {K. R.} and Martin Perlman and Munshi, {Nikhil C.} and Bart Barlogie",

year = "1998",

doi = "10.1046/j.1365-2141.1998.00976.x",

language = "English",

volume = "103",

pages = "530--532",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Anti-myeloma activity of pamidronate in vivo

AU - Dhodapkar, Madhav V.

AU - Singh, Joginder

AU - Mehta, Jayesh

AU - Fassas, Athanasios

AU - Desikan, K. R.

AU - Perlman, Martin

AU - Munshi, Nikhil C.

AU - Barlogie, Bart

PY - 1998

Y1 - 1998

N2 - Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (≥20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.

AB - Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (≥20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and >50% reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.

KW - Bisphosphonates

KW - Bone

KW - Growth

KW - Myeloma

KW - Pamidronate

UR - http://www.scopus.com/inward/record.url?scp=0031782314&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1998.00976.x

DO - 10.1046/j.1365-2141.1998.00976.x

M3 - Article

C2 - 9827929

AN - SCOPUS:0031782314

SN - 0007-1048

VL - 103

SP - 530

EP - 532

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Anti-myeloma activity of pamidronate in vivo

Abstract

Keywords

Access to Document

Fingerprint

Cite this